Merck Debt to Equity Ratio 2010-2022 | MRK

Current and historical debt to equity ratio values for Merck (MRK) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Merck debt/equity for the three months ending September 30, 2022 was 0.64.
Merck Debt/Equity Ratio Historical Data
Date Long Term Debt Shareholder's Equity Debt to Equity Ratio
2022-09-30 $62.56B $44.52B 1.41
2022-06-30 $63.78B $43.32B 1.47
2022-03-31 $65.72B $40.95B 1.61
2021-12-31 $67.44B $38.26B 1.76
2021-09-30 $57.63B $35.86B 1.61
2021-06-30 $57.30B $33.39B 1.72
2021-03-31 $63.81B $27.04B 2.36
2020-12-31 $66.18B $25.40B 2.61
2020-09-30 $60.53B $29.27B 2.07
2020-06-30 $62.87B $27.74B 2.27
2020-03-31 $58.61B $26.30B 2.23
2019-12-31 $58.40B $26.00B 2.25
2019-09-30 $56.41B $26.93B 2.10
2019-06-30 $56.23B $27.74B 2.03
2019-03-31 $54.68B $27.67B 1.98
2018-12-31 $55.76B $26.88B 2.07
2018-09-30 $52.47B $32.66B 1.61
2018-06-30 $52.27B $32.77B 1.60
2018-03-31 $52.14B $33.90B 1.54
2017-12-31 $53.30B $34.57B 1.54
2017-09-30 $53.18B $38.50B 1.38
2017-06-30 $53.09B $39.71B 1.34
2017-03-31 $56.47B $40.09B 1.41
2016-12-31 $55.07B $40.31B 1.37
2016-09-30 $54.38B $43.96B 1.24
2016-06-30 $53.03B $43.45B 1.22
2016-03-31 $54.85B $43.90B 1.25
2015-12-31 $56.91B $44.77B 1.27
2015-09-30 $55.55B $45.68B 1.22
2015-06-30 $55.94B $46.64B 1.20
2015-03-31 $60.43B $47.92B 1.26
2014-12-31 $49.38B $48.79B 1.01
2014-09-30 $56.45B $45.36B 1.24
2014-06-30 $49.34B $48.52B 1.02
2014-03-31 $55.90B $52.56B 1.06
2013-12-31 $53.32B $52.33B 1.02
2013-09-30 $56.41B $50.01B 1.13
2013-06-30 $56.77B $50.11B 1.13
2013-03-31 $50.59B $55.61B 0.91
2012-12-31 $50.67B $55.46B 0.91
2012-09-30 $48.09B $58.21B 0.83
2012-06-30 $47.85B $57.67B 0.83
2012-03-31 $48.20B $57.31B 0.84
2011-12-31 $48.19B $56.94B 0.85
2011-09-30 $48.94B $57.60B 0.85
2011-06-30 $48.27B $57.92B 0.83
2011-03-31 $49.03B $56.84B 0.86
2010-12-31 $48.98B $56.81B 0.86
2010-09-30 $49.79B $58.05B 0.86
2010-06-30 $48.51B $57.67B 0.84
2010-03-31 $51.25B $60.34B 0.85
2009-12-31 $50.83B $61.49B 0.83
2009-09-30 $23.39B $25.35B 0.92
2009-06-30 $26.67B $22.74B 1.17
2009-03-31 $24.54B $22.00B 1.12
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $278.995B $48.704B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $467.679B 18.00
Eli Lilly (LLY) United States $356.089B 44.94
AbbVie (ABBV) United States $289.429B 12.00
Novo Nordisk (NVO) Denmark $287.171B 37.66
Pfizer (PFE) United States $285.774B 7.81
Novartis AG (NVS) Switzerland $199.112B 15.00